title: Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
authors.affiliation: Department of Pediatrics, Division of Gastroenterology and Nutrition, Weill Cornell Medical College, New York, NY 10065, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Jordan
authors.forename: Alpana
authors.initials: A
authors.lastname: Waghmare
authors.forename: Alain S
authors.initials: AS
authors.lastname: Abi-Ghanem
authors.forename: Aeri
authors.initials: A
authors.lastname: Moon
authors.forename: Christine M
authors.initials: CM
authors.lastname: Salvatore
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D015270:Mycobacterium avium-intracellulare Infection / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab